Paola Bozzatello1, Silvio Bellino2, Irene Mancini3, Luisa Sandei3, Enrico Zanalda4, Paola Rocca3,5. 1. Center for Personality Disorders, Department of Neuroscience, "Rita Levi Montalcini", University of Turin, Via Cherasco 11, 10126, Turin, Italy. 2. Center for Personality Disorders, Department of Neuroscience, "Rita Levi Montalcini", University of Turin, Via Cherasco 11, 10126, Turin, Italy. silvio.bellino@unito.it. 3. Department of Neuroscience, "Rita Levi Montalcini", University of Turin, Turin, Italy. 4. Department of Mental Health, A.S.L. TO 3, Turin, Italy. 5. Department of Neuroscience and Mental Health, S.S. D. Coordinamento Assistenziale Psichiatrico Ospedale-Territorio, A.O.U. Città della Salute e della Scienza di Torino-Molinette, Turin, Italy.
Abstract
BACKGROUND AND OBJECTIVE: Clinical practice guidelines recommend antipsychotic monotherapy, including oral and long-acting formulations, in the treatment of schizophrenia. This open-label, randomized, controlled trial aimed to evaluate the efficacy and tolerability in patients with schizophrenia of once-monthly long-actingpaliperidone palmitate (PP1M) compared with oral paliperidone extended release (ER), with a particular focus on satisfaction, subjective well-being, and service engagement. METHODS:Seventy-two consecutive outpatients with schizophrenia (DSM-5) were randomly assigned for 6 months to: (1) PP1M (50-150 mg equivalent) or (2) paliperidone ER (6-12 mg/day). Participants were assessed at baseline and after 6 months with the Treatment Satisfaction Questionnaire for Medication (TSQM); the Subjective Well-being under Neuroleptics Scale (SWN-K); the Service Engagement Scale (SES); the Clinical Global Impression-Schizophrenia (CGI-SCH); and the Personal and Social Performance (PSP) score. ANOVA repeated measures was performed. Intention-to-treat analysis with last observation carried forward was conducted. RESULTS: We found a significant within-subjects effect (trial duration) for all rating scale except for cognitive symptoms and the TSQM domain "side effects". A significant effect between subjects (treatment modality) was found for the CGI negative symptoms, the TSQM domains "overall satisfaction" and "convenience," and the SES. There were seven drop-outs (9.7%): twi due to hyperprolactinemia and five for lack of compliance. CONCLUSIONS: Significant differences between the two formulations were found. PP1M was superior to paliperidone ER on global treatment satisfaction and convenience, on service engagement, and in reducing negative symptoms. The trial was registered in the Australian New Zealand Clinical Trials Registry (ANZCTR) with the code: ACTRN12618001113246.
RCT Entities:
BACKGROUND AND OBJECTIVE: Clinical practice guidelines recommend antipsychotic monotherapy, including oral and long-acting formulations, in the treatment of schizophrenia. This open-label, randomized, controlled trial aimed to evaluate the efficacy and tolerability in patients with schizophrenia of once-monthly long-acting paliperidone palmitate (PP1M) compared with oral paliperidone extended release (ER), with a particular focus on satisfaction, subjective well-being, and service engagement. METHODS: Seventy-two consecutive outpatients with schizophrenia (DSM-5) were randomly assigned for 6 months to: (1) PP1M (50-150 mg equivalent) or (2) paliperidone ER (6-12 mg/day). Participants were assessed at baseline and after 6 months with the Treatment Satisfaction Questionnaire for Medication (TSQM); the Subjective Well-being under Neuroleptics Scale (SWN-K); the Service Engagement Scale (SES); the Clinical Global Impression-Schizophrenia (CGI-SCH); and the Personal and Social Performance (PSP) score. ANOVA repeated measures was performed. Intention-to-treat analysis with last observation carried forward was conducted. RESULTS: We found a significant within-subjects effect (trial duration) for all rating scale except for cognitive symptoms and the TSQM domain "side effects". A significant effect between subjects (treatment modality) was found for the CGI negative symptoms, the TSQM domains "overall satisfaction" and "convenience," and the SES. There were seven drop-outs (9.7%): twi due to hyperprolactinemia and five for lack of compliance. CONCLUSIONS: Significant differences between the two formulations were found. PP1M was superior to paliperidone ER on global treatment satisfaction and convenience, on service engagement, and in reducing negative symptoms. The trial was registered in the Australian New Zealand Clinical Trials Registry (ANZCTR) with the code: ACTRN12618001113246.
Authors: Pablo Barrio; Albert Batalla; Pere Castellví; Diego Hidalgo; Marta García; Ana Ortiz; Iria Grande; Alexandre Pons; Eduard Parellada Journal: Int Clin Psychopharmacol Date: 2013-07 Impact factor: 1.659
Authors: Luisa Peters; Amanda Krogmann; Laura von Hardenberg; Katja Bödeker; Viktor B Nöhles; Christoph U Correll Journal: Curr Psychiatry Rep Date: 2019-11-19 Impact factor: 5.285